rAAV Packaging Service, Large Scale


  • Catalog #: SL100862
  • Unit Size: 1.0 mL (>1X1013 VG/mL)

AAV Packaging Service in Large Scale

Features:
- Nonpathogenic with least immune response and best suitable for in vivo application.
- Excellent gene delivery efficiency in most cell types including dividing and non-dividing or primary cells.
- Persistent transgene expression.
- Multiple serotypes (AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-DJ/8 and AAV-DJ).

Service Description:
- rAAV packaging in 2xcell stack.
- rAAV purification via advanced 2xCsCl ultra-centrifugation.
-
Desalting, filter sterilization and AAV titration via qPCR.


rAAV Serotypes We Offer:
AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-PHP.B, AAV-DJ/8 and AAV-DJ.

Required Materials:
AAV cis plasmid carrying your gene of interest (GOI), >300
µg.

Turnaround Time: 1 ~ 2 weeks.

Deliverables: >1.0 mL of super purified in vivo grade rAAV vector at >1E+13 VG/mL*.

We offer discount for new customer, please request a quote with us today.

Service Inquiry / Request a Quote

Super High Yield:
With our proprietary genetically engineered AAV·HT™ packaging cell and a modified rAAV cis vector, the rAAV yield is easy to reach super high level--------total 1E+15 VG. For super high level rAAV production up to 1E+15 VG total, please contact us to request a quote.

 


Figure 1. A comparison of purity and infectivity of rAAV vectors from different sources showing super purified and super infectious (close to clinical trial grade) rAAV vector prepared via our advanced double CsCl ultra-centrifugation approach. 

A. rAAV vectors (total 1E+9 VG per lane)  from different sources were resolved on SDS-PAGE followed by silver staining.  Lane 1: GMP manufactured rAAV vector from CHOP; Lane 2: rAAV prepared via our advanced 2xCsCl ultra-centrifugation approach; Lane 3: rAAV from Vector Core of BCM; Lane 4: rAAV from our competitor "V"; Lane 5: rAAV from our competitor "C"; Lane 6: Protein marker.
B. Super infectious rAAV vector prepared via advanced double CsCl ultra-centrifugation.  Left panel: rAAV9-GFP (total 5E+9 VG) from our competitor "V" injected to mouse eye; Right panel: rAAV-9-GFP (total 5E+9 VG) purified via advanced 2xCsCl ultra-centrifugation injected to mouse eye. 


Figure 2. A comparison of infectivity of rAAV vectors from different sources showing super purified rAAV prepared via advanced double CsCl ultra-centrifugation approach is super infectious.

rAAV1-GFP (total 2E+9 VG) from different sources were injected to mouse muscle tissue.  The GFP fluorescence was visualized 3 weeks post injection.  A. rAAV1-GFP from our competitor "V"; B. rAAV1-GFP from our pre-made rAAVs stock purified via advanced double CsCl ultra-centrifugation.  C. Quantification data showed that our super purified rAAV (bar 2) is ~ 9 times more infectious than that (bar 1) prepared via conventional CsCl ultra-centrifugation.  


* Final viral yield may depend on the nature of transgene.





Copyright © 2017 SignaGen Laboratories. All Rights Reserved.